Xtant Medical (XTNT) Q4 2024 earnings summary

Executive summary

• Achieved record Q4 revenue of $31.5 million and full-year revenue of $117.3 million in 2024, reflecting 12% quarter-over-quarter and 28% year-over-year growth, driven by organic growth, Surgalign integration, and strong biologics performance.

• Net loss for 2024 was $16.4 million ($0.12/share), compared to net income of $660,000 ($0.01/share) in 2023, which included an $11.7 million gain on bargain purchase.

• Adjusted EBITDA for 2024 was a loss of $2.3 million, compared to a $1.4 million loss in 2023, with Q4 adjusted EBITDA positive at $438,000.

• Operating expenses were reduced by over $5 million since August/Q3 2024, including a 13% headcount reduction and facility consolidation, with some savings reinvested for growth.

• Operational efficiencies led to over $500,000 in Q4 operating cash flow.

Financial highlights

• Q4 2024 revenue rose to $31.5 million from $28.1 million in Q4 2023, with biologics up 21% year-over-year and hardware down 10%.

• Q4 gross margin was 50.8%, down from 61% in Q4 2023, impacted by a $1.5 million inventory charge and reduced production yields.

• Full-year 2024 gross margin was 58.2%, down from 60.8% in 2023, primarily due to reduced production throughput and inventory write-offs.

• Operating expenses for 2024 were $80.3 million, up from $65.6 million in 2023, mainly due to higher commissions, compensation, amortization, and R&D.

• Cash and equivalents at year-end: $6.2 million; net accounts receivable: $20.7 million; inventory: $38.6 million; $4.2 million available under credit facilities.

Outlook and guidance

• 2025 revenue guidance is $126–130 million (7–11% growth), with mid-double-digit growth expected in biologics and hardware revenue expected to be flat to modestly down.

• Gross margin expected to improve by 4–5 points by Q4 2025, driven by new product launches and increased direct channel sales.

• Free cash flow generation is expected to begin in the second half of 2025, with no need for additional external capital.